Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

5 Most Oversold S&P 500 Stocks So Far in 2026

AI-generated analysis

πŸ“‰ Boston Scientific (BSX) shares have declined 55.15% from their 52-week high, marking it as one of the most oversold S&P 500 stocks in 2026.

⚠️ Wolfe Research downgraded BSX from Outperform to Peer Perform on May 29, ending a four-year bullish outlook for the firm.

🩺 The downgrade follows Boston Scientific's announcement that sales growth for its Watchman implant is slowing due to reduced stroke risk.

πŸ“Š Analysts now anticipate 7% organic growth for BSX in 2027, which would value the stock at roughly $50 per share.

πŸ’° TD Cowen lowered its price target on BSX from $80 to $61 but maintained its Buy rating despite the recent revisions.

πŸ“ˆ Despite negative analyst actions, BSX remains a Strong Buy based on 27 analysts with an average upside of 70% as of May 29.

πŸ₯ Boston Scientific is a global medical technology company that manufactures and markets devices for various interventional medical specialties.

Bullish Signals
  • Despite recent analyst downgrades, BSX remains a Strong Buy based on recommendations from 27 analysts.
  • The stock has an average share price upside of 70% as of the close on May 29, indicating significant potential for growth.
  • TD Cowen maintained a Buy rating on the stock even after lowering its price target to $61 from $80.
Risk Factors
  • Wolfe Research downgraded the stock from Outperform to Peer Perform on May 29, ending a four-year bullish outlook due to slowing sales growth for the Watchman implant.
  • TD Cowen lowered its price target on BSX to $61 from $80 following the Watchman update, reflecting reduced analyst valuation expectations.
  • Wolfe Research now anticipates only 7% organic growth for Boston Scientific in 2027, suggesting a slowdown in future revenue expansion.
Full Analysis
Boston Scientific Corporation (NYSE: BSX) is identified as one of the five most oversold S&P 500 stocks in 2026, having experienced a share price decline of 55.15% from its 52-week high. The stock's recent performance was influenced by a downgrade from Wolfe Research on May 29, which shifted its rating from Outperform to Peer Perform after the company reported slowing sales growth for its Watchman implant, a device used to reduce stroke risk. This marks the end of a four-year bullish outlook from the firm. Following the Watchman update, TD Cowen also lowered its price target on BSX to $61 from $80, though it maintained a Buy rating. Despite these analyst revisions, the stock remains rated as a Strong Buy by 27 analysts with an average share price upside of 70% as of May 29. Boston Scientific is described as a global medical technology company that manufactures and markets devices for various interventional medical specialties.